CYSTATIN-C - AS A PREDICTOR OF EARLY DIAGNOSIS OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (sighting article)
Keywords:
Cystatin S, diabetic nephropathy, diabetes mellitus, rapid glomerular filtration, chronic kidney disease, meta-analysisAbstract
Cystatin-C is an endogenous protein of low molecular weight, produced in all nucleated cells, and excreted from the body only through the kidneys. It does not accumulate in the blood vessels, tissues and proximal tubules after excretion, and is completely excreted by the kidneys. It is this property of Cystatin-C that prevents the development of Diabetic Nephropathy (DN), which is one of the 4 complications that seriously affect the quality of life of patients with diabetes, by other methods (creatinine, urea, microproteinuria and their patient age, gender, body combined formulas based on indicators such as weight...) with higher accuracy and reliable diagnosis even in the initial (hidden) period of the development of diabetic nephropathy. Because in the synthesis and excretion of Cystatin-C, indicators such as race, age, gender, body weight of the patient are not important. Therefore, KDIGO experts consider the method of calculation together with Cystatin-C to be the most preferred method for calculating eGFR.
References
Internist/ru https://internist.ru/publications/detail/kreatinin-i-cistatin-c---markery-ocenki-funkcii-pochek/
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. KidneyIntSuppl. 2013;3(1):1-150.
Medical Center of the Graduate School, Nanchang University; bDepartment of Nephrology, the Second Affiliated Hospital of Nanchang University, Nanchang, China https://karger.com/kbr/article/41/6/919/183569/Clinical-Utility-of-Serum-Cystatin-C-in-Predicting
Otu HH, Can H, Spentzos D, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. DiabetesCare. 2007;30(3):638–643. doi: 10.2337/dc06-1656
[5]Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011;54:1335–1340.
[6]United States Renal Data System, USRDS 2015 Annual Data Report.
Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J KidneyDis. 2011;58(3):356-65. doi: 10.1053/j.ajkd.2011.02.389
Алимов А.В., Бегматова Х.А., Каюмова Д.Т., Айходжаева М.А., Джураева А.Ш. https://cyberleninka.ru/article/n/tsistatin-s-vozmozhnosti-ranney-diagnostike-nefropatii-u-bolnyh-sd-tip-2
Бикбов Б.Т., Томилина Н.А.. Заместительная терапия больных с хронической почечной недостаточностью в Российской Федерации в 1998–2011 гг. Нефрологиаидиализ. 2014; 16 (1): 11-117
Вельков В.В. Цистатин с и NGAL – маркеры преклинической ренальной дисфункции и субклинического острого повреждения почек // Лабораторная служба. – 2015. – Т. 4. – №2. – С. 38-43. [Vel'kov V.V. Cystatin C and NGAL – the markers of preclinical renal dysfuction and subclinical acute kidney injury. Laboratornayasluzhba. 2015;4(2):38-43. (In Russ.)] doi: 10.17116/labs20154238-43
Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 8-й выпуск // Сахарный диабет. – 2017. – Т. 20. – №1S. – C. 1-121. [Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetesmellitus. 2017;20(1S):1-121. (InRuss.)] doi: 10.14341/DM8146
Ж.Д. Кобалава, Ю.В. Котовская*, С.В. Виллевальде. Методы оценки функционального состояния почек при артериальной гипертонии: клиническое значение и практическое применение. https://cyberleninka.ru/article/n/metody-otsenki-funktsionalnogo-sostoyaniya-pochek-pri-arterialnoy-gipertonii-klinicheskoe-znachenie-i-prakticheskoe-primenenie/viewer
Климонтов В.В., Еременко Н.В., Мякина Н.Е., Фазуллина О.Н. Цистатин С и коллаген IV типа в диагностике хронической болезни почек у больных сахарным диабетом 2 типа https://www.dia-endojournals.ru/jour/article/view/6701/5016
Моисеев В.С., Мухин Н.А., Смирнов А.В. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции // Российский кардиологический журнал. – 2014. – №8. – С. 7-37. [Moiseev VC, Mukhin NA, Smirnov AV. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Russian Journal of Cardiology. 2014;(8):7-37. (In Russ.)] doi: 10.15829/1560-4071-2014-8-7-37
